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Abstract
Background:  Epidermal keratinocytes continuously proliferate and differentiate to form the
mechanical and water permeability barrier that makes terrestrial life possible. In certain skin
diseases, these processes become dysregulated, resulting in abnormal barrier formation. In
particular, skin diseases such as psoriasis, actinic keratosis and basal and squamous cell carcinomas
are characterized by hyperproliferation and aberrant or absent differentiation of epidermal
keratinocytes. We previously demonstrated that 8-Cl-adenosine (8-Cl-Ado) can induce
keratinocyte growth arrest without inducing differentiation. 
Results: To determine if this agent might be useful in treating hyperproliferative skin disorders,
we investigated whether 8-Cl-Ado could enhance the ability of 1,25-dihydroxyvitamin D3
[1,25(OH)2D3], a known keratinocyte differentiating agent and a clinical treatment for psoriasis, to
inhibit keratinocyte growth. We found that low concentrations of 8-Cl-Ado and 1,25(OH)2D3
appeared to act additively to reduce proliferation of primary mouse epidermal keratinocytes.
However, another agent (transforming growth factor-beta) that triggers growth arrest without
inducing differentiation also coincidentally inhibits differentiation elicited by other agents; inhibition
of differentiation is suboptimal for treating skin disorders, as differentiation is often already
reduced. Thus, we determined whether 8-Cl-Ado also decreased keratinocyte differentiation
induced by 1,25(OH)2D3, as measured using the early and late differentiation markers, keratin 1
protein levels and transglutaminase activity, respectively. 8-Cl-Ado did not affect 1,25(OH)2D3-
stimulated keratin 1 protein expression or transglutaminase activity. 
Conclusions:  Our results suggest that 8-Cl-Ado might be useful in combination with
differentiating agents for the treatment of hyperproliferative disorders of the skin.
Background
The epidermis of the skin serves as a mechanical and water
permeability barrier essential for terrestrial life (reviewed
in [1]) and is composed primarily of epidermal
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keratinocytes. These keratinocytes stratify to form several
layers. The deepest layer, the stratum basalis or basal layer
comprises proliferating cells that continuously divide to
regenerate cells lost to the environment. As the cells
migrate upward into the first differentiated layer, the stra-
tum spinousum or spinous layer, they cease proliferating
and begin to express the intermediate filament proteins,
the mature keratins 1 and 10. This early differentiation is
followed by a late differentiation program in the stratum
granulosum or granular layer, which is marked by the
expression of other structural proteins, such as filaggrin
and loricrin, and by increased activity of the enzyme,
transglutaminase, which forms highly durable γ-glutamyl-
ε-lysyl bonds to cross-link the proteins into a tough and
resistant shell underneath the plasma membrane. At the
boundary of the granular layer and the outermost stratum
corneum, or cornified layer, the keratinocytes terminally
differentiate, degrading their nuclei and other organelles
and releasing lamellar bodies, the lipid contents of which
form a water-impermeant barrier. The squames, the flat-
tened remnants of the keratinocytes, and the lipids from
the lamellar bodies form a sort of brick and mortar, to pre-
vent water loss, microbial invasion and/or other mechan-
ical insults (reviewed in [2-4]).
1,25-Dihydroxyvitamin D3  [1,25(OH)2D3] is a known
regulator of this process of keratinocyte growth and differ-
entiation (reviewed in [2,5]). In vitro, 1,25(OH)2D3 inhib-
its keratinocyte proliferation and stimulates the
expression of numerous keratinocyte differentiation
markers (reviewed in [2,6]). In vivo a physiologic role for
1,25(OH)2D3 in regulating keratinocyte differentiation is
suggested by several lines of evidence: (1) keratinocytes
express both the 25-hydroxylase and the 1α-hydroxylase
which converts inactive vitamin D3 to its active 1,25-dihy-
droxy metabolite (reviewed in [2,6]); (2) receptors for
1,25(OH)2D3 are present in the skin and in epidermal
keratinocytes in vitro [7-11]; and (3) Vitamin D receptor
null mice exhibit altered skin function, characterized by
abnormal hair follicles and reduced expression of several
keratinocyte differentiation markers [12]. Furthermore,
1,25(OH)2D3 and its structural analogs have been used as
effective treatments for psoriasis, a human skin disease
characterized by inflammation and by hyperproliferation
and abnormal differentiation of keratinocytes (reviewed
in [13,14]).
8-Chloro-cyclic-adenosine monophosphate (8-Cl-cAMP)
is known to inhibit growth and to induce apoptosis in a
variety of cancer cells [15-18], suggesting its potential util-
ity as an anti-cancer drug. Indeed, phase I trials with 8-Cl-
cAMP have been performed ([19,20] and reviewed in
[21]) and phase II trials are in progress [22]. However, the
mechanisms by which this agent acts are incompletely
understood, and several investigators have proposed that
an 8-Cl-cAMP metabolite, 8-chloro-adenosine (8-Cl-Ado)
is the active anti-proliferative compound [16,23]. Indeed,
8-Cl-Ado has been shown to inhibit growth in a variety of
cell types [24-28].
Previously, we demonstrated that 8-Cl-Ado arrests the
growth of primary mouse epidermal keratinocytes with-
out triggering differentiation [29]. Thus, 8-Cl-Ado func-
tions in an analogous fashion to transforming growth
factor-β (TGF-β), which also triggers growth arrest, but not
differentiation,, of keratinocytes (reviewed in [30]). In
contrast with a polypeptide such as TGF-β, 8-Cl-Ado, as a
small molecule rather than a protein, could potentially be
taken orally or applied topically to skin. Thus, 8-Cl-Ado
may represent a novel therapy for treatment of skin disor-
ders, such as psoriasis, actinic keratoses and basal and
squamous cell carcinomas, characterized by hyperprolif-
eration of keratinocytes. One potential problem, however,
is that TGF-β also inhibits the expression of differentiation
markers elicited by other differentiating agents [31]. Since
another characteristic typical of hyperproliferative skin
diseases such as psoriasis is impaired differentiation [32],
a therapy that inhibits both proliferation and differentia-
tion would be less than ideal.
To determine whether 8-Cl-Ado, as a potent keratinocyte
growth arrestor, could potentially be used to treat hyper-
proliferative skin diseases in combination with a current
treatment, we investigated the effect of 8-Cl-Ado on
1,25(OH)2D3-induced inhibition of keratinocyte prolifer-
ation and stimulation of keratinocyte differentiation. We
found that low concentrations of 8-Cl-Ado acted addi-
tively with 1,25(OH)2D3 to inhibit DNA synthesis, with-
out affecting the ability of 1,25(OH)2D3  to enhance
keratin 1 expression, a marker of early differentiation, or
transglutaminase activity, a marker of late differentiation.
Thus, our results suggest that a combination therapy with
1,25(OH)2D3 and 8-Cl-Ado could potentially be an effec-
tive treatment for hyperproliferative skin disorders includ-
ing psoriasis, actinic keratosis and non-melanoma skin
cancers.
Results and discussion
To determine if 8-Cl-Ado could function with the growth
inhibiting agent 1,25(OH)2D3 to enhance its antiprolifer-
ative effect, we incubated primary epidermal keratinocytes
for 24 hours with various concentrations of 8-Cl-Ado in
the presence and absence of low concentrations of
1,25(OH)2D3 prior to assessing effects on de novo DNA
synthesis as measured by [3H]thymidine incorporation
into DNA. As shown in Figure 1A, 8-Cl-Ado inhibited
[3H]thymidine incorporation at concentrations of 5–25
µM with an estimated half-maximal inhibitory concentra-
tion (IC50) of 5 µM. This value agrees well with our previ-
ously determined IC50 of 7.5 µM [29]. In agreement withBMC Pharmacology 2004, 4:13 http://www.biomedcentral.com/1471-2210/4/13
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8-Cl-Ado and 1,25(OH)2D3 Inhibit Keratinocyte Proliferation Figure 1
8-Cl-Ado and 1,25(OH)2D3 Inhibit Keratinocyte Proliferation. Near-confluent primary mouse epidermal keratinocytes 
were treated with the indicated concentrations of (A) 8-Cl-Ado or (B) 1,25(OH)2D3 for 24 hours, and [3H]thymidine incorpo-
ration was determined as indicated in Materials and Methods. Data represent the mean ± SEM of five experimentsperformed in 
triplicate; *p < 0.05, **p < 0.01 versus the control value.
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previous reports [33,34], 1,25(OH)2D3  also inhibited
DNA synthesis at concentrations of 1 to 100 nM with an
estimated IC50 of approximately 4 nM (Figure 1B). As
shown in Figure 2, when the two agents were combined,
their effect on DNA synthesis appeared to be additive, as
evidenced by the comparable slopes of the [3H]thymidine
incorporation curves at the three different concentrations
of 0 (a portion of which is replotted from Figure 1), 1 and
10 nM 1,25(OH)2D3. The combination of 1 or 5 µM 8-Cl-
Ado with 10 nM 1,25(OH)2D3 yielded a greater inhibition
than 8-Cl-Ado alone, and conversely, the combined effect
of 5 and 10 µM 8-Cl-Ado with 1 nM 1,25(OH) 2D3 was
significantly larger than 1 nM 1,25(OH)2D3 alone. Impor-
tantly, the combination of 10 nM 1,25(OH)2D3 with 10
µM 8-Cl-Ado produced an inhibition of [3H]thymidine
incorporation that was significantly greater than that elic-
ited by either agent alone. Indeed, the inhibition elicited
by 10 µM 8-Cl-Ado and 10 nM 1,25(OH)2D3 was compa-
rable to the inhibition produced by 100 nM 1,25(OH)2D3
alone (compare Figures 1B and 2). Thus, our results sug-
gest that not only does 8-Cl-Ado not prevent the growth
inhibitory action of 1,25(OH)2D3, but, in fact, the two
agents seem to act in an additive fashion to more effec-
tively inhibit keratinocyte proliferation.
TGF-β, another agent that, like 8-Cl-Ado, induces growth
arrest but not differentiation of keratinocytes ([31] and
reviewed in [30]), can inhibit the ability of differentiating
agents to elicit keratinocyte differentiation [31]. However,
for an agent to have therapeutic potential as a treatment
8-Cl-Ado and 1,25(OH)2D3 Act Additively to Inhibit Keratinocyte Proliferation Figure 2
8-Cl-Ado and 1,25(OH)2D3 Act Additively to Inhibit Keratinocyte Proliferation. Near-confluent primary mouse epi-
dermal keratinocytes were treated with the indicated concentrations of 8-Cl-Ado in the presence of no (closed circles), 1 nM 
(open squares) or 10 nM (open triangles) 1,25(OH)2D3 for 24 hours, and [3H]thymidine incorporation was determined as indi-
cated in Materials and Methods. Data represent the mean ± SEM of five experiments performed in triplicate; *p < 0.05, **p < 
0.01 versus the control value, †p < 0.01 versus the corresponding concentration of 1,25(OH)2D3 alone, §p < 0.01 versus the 
corresponding concentration of 8-Cl-Ado alone.
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for hyperproliferative skin disorders, such an inhibition of
differentiation would be counterproductive to its efficacy
as a medication. To determine if 8-Cl-Ado also inhibited
keratinocyte differentiation, we investigated whether 8-
Cl-Ado inhibited the ability of 1,25(OH)2D3 to induce the
late differentiation marker, transglutaminase activity. For
this experiment we chose the concentrations of 8-Cl-Ado
(10 µM) and 1,25(OH)2D3 (10 nM) shown in Figure 2 to
produce a greater growth inhibition than either agent
alone. As illustrated in Figure 3, 10 µM 8-Cl-Ado alone
had little or no effect on transglutaminase activity, as
reported previously [29]. On the other hand, 10 nM
1,25(OH)2D3  significantly elevated transglutaminase
activity by approximately 75%. The combination of 8-Cl-
Ado and 1,25(OH)2D3was not significantly different from
1,25(OH)2D3 alone, with a significant approximate 60%
increase relative to the control value. Thus, our results
indicate that 8-Cl-Ado did not prevent the differentiative
effect of 1,25(OH)2D3, suggesting that these two agents
might be combined to treat keratinocyte hyperprolifera-
tive disorders, such as psoriasis.
8-Cl-Ado Has No Effect on 1,25(OH)2D3-Stimulated Transglutaminase Activity Figure 3
8-Cl-Ado Has No Effect on 1,25(OH)2D3-Stimulated Transglutaminase Activity. Near-confluent primary mouse 
epidermal keratinocytes were treated with and without 10 µM 8-Cl-Ado in the presence and absence of 10 nM 1,25(OH)2D3 
for 24 hours, and transglutaminase activity was determined as indicated in Materials and Methods. Data represent the mean ± 
SEM of four experiments performed in triplicate; *p < 0.01 versus the control value.
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Transglutaminase activity is a marker of late keratinocyte
differentiation. We also examined the effect of 8-Cl-Ado
on a marker of early keratinocyte differentiation, namely
keratin 1 protein expression, using an even higher concen-
tration of 8-Cl-Ado (25 µM). Western analysis demon-
strated that 1,25(OH)2D3 induced an approximate 45%
increase in keratin 1 protein levels with the combination
of 1,25(OH)2D3 and 8-Cl-Ado producing a comparable
46% increase (Figure 4). Thus, early differentiation in
response to 1,25(OH)2D3 also was not affected by 8-Cl-
Ado. Interestingly, however, in contrast to previous results
[29], in these experiments 8-Cl-Ado alone elicited a small
but significant increase in keratin 1 protein expression
(32%). The reason for this disparity is unclear but may
result from differences in the lot of anti-keratin 1 antibody
used in the western analysis and/or the increased sensitiv-
ity of the method used for detecting and quantifying
immunoreactive protein in this work.
Most current treatments for psoriasis suffer from one or
more disadvantages including lack of efficacy, contraindi-
cations due to deleterious side effects and/or aesthetic
deficiencies ([35] and reviewed in [36]). Indeed, mono-
therapies tend to be less efficacious than combination
therapies with two or more agents used concurrently,
sequentially or in a rotational fashion (reviewed in [36]).
Treatment with 1,25(OH)2D3 and its analogs has proven
successful, although the possibility of toxicity as the result
of 1,25(OH)2D3's ability to affect calcium metabolism has
led to the search for topically effective analogs with little
or no effect on serum calcium levels (reviewed in [32]). If
the amount of 1,25(OH)2D3 (or its analog) required for
treatment could be reduced, this decrease in dosage would
presumably minimize systemic effects on calcium, which
is the primary dose-limiting factor in the use of
1,25(OH)2D3 analogs in the treatment of psoriasis [32].
Thus, our results indicating that 8-Cl-Ado enhances the
growth inhibitory effect of 1,25(OH)2D3, a known kerati-
nocyte differentiating agent and possible treatment for
psoriasis [32], suggests the potential for combination
therapy. Moreover, the fact that 8-Cl-Ado does not inter-
fere with the promotion of differentiation by
1,25(OH)2D3 further supports the possible combined use
of these two agents for treatment of hyperproliferative
skin disorders.
Several lines of evidence suggest that 8-Cl-Ado is not sim-
ply acting through cyototoxicity to inhibit keratinocyte
growth. First, we have previously shown that 8-Cl-Ado
growth arrests keratinocytes in the G0/G1 phase of the cell
cycle with no increase in the sub-G0/G1 (apoptotic) popu-
lation of cells [29]. Second, we also showed that the effect
of 8-Cl-Ado to inhibit proliferation is reversible in that
washout of the compound returned DNA synthesis essen-
tially to basal (untreated) levels [29]. Finally, in this report
we demonstrate that 8-Cl-Ado did not inhibit the
1,25(OH)2D3-stimulated increase in transglutaminase
activity (Figure 3) or keratin 1 protein expression (Figure
4). Together, these results indicate that 8-Cl-Ado is acting
in a specific manner to decrease keratinocyte
proliferation.
Nevertheless, the mechanism by which 8-Cl-Ado exerts its
growth inhibitory effects in keratinocytes is not clear. Our
previous results indicate that 8-Cl-Ado must enter the cells
to trigger growth arrest, since inhibiting uptake with an
adenosine transporter, NBTI, prevented the arrest in the
G0/G1 phase of the cell cycle [29]. We also reported in a
prior publication that 8-Cl-Ado induced the expression of
the cyclin-dependent kinase inhibitor, p21 [29], which is
known to contribute to growth arrest in keratinocytes and
other cell types ([37] and reviewed in [30]). However,
other investigators have reported 8-Cl-Ado-mediated
inhibitory effects on RNA synthesis and the levels of cellu-
lar ATP [16]. Clearly, further research is necessary to
define the pathways used by 8-Cl-Ado to regulate kerati-
nocyte proliferation.
Conclusions
In summary, our data show that 8-Cl-Ado functions with
the keratinocyte-differentiating agent 1,25(OH)2D3  to
inhibit keratinocyte proliferation without altering the
ability of 1,25(OH)2D3 to induce differentiation. Thus,
our results support the possibility of using 8-Cl-Ado alone
or in combination with differentiating agents such as
1,25(OH)2D3 or its analogs to treat hyperproliferative
keratinocyte disorders including psoriasis.
Methods
Materials
Tissue culture reagents were obtained from standard sup-
pliers as indicated in a previous publication [29].
1,25(OH)2D3 was a generous gift of Dr. Maurice Pechet
(Research Institute for Medicine and Chemistry, Cam-
bridge, MA). 8-Cl-Ado was obtained from Biolog (La Jolla,
CA). [3H]Thymidine and [3H]putrescine were purchased
from Dupont/NEN (Boston, MA). Dimethylated casein
was obtained from Sigma (St. Louis, MO). All other rea-
gents were from standard suppliers.
Keratinocyte culture
Primary cultures of mouse epidermal keratinocytes were
prepared from neonatal ICR CD-1 mice and cultivated in
a 25 µM calcium-containing serum-free keratinocyte
medium as in [29].
Measurement of DNA synthesis
For measurement of [3H]thymidine incorporation into
DNA, as in [29], near-confluent cultures were refed with
SFKM containing various concentrations of 8-Cl-Ado withBMC Pharmacology 2004, 4:13 http://www.biomedcentral.com/1471-2210/4/13
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8-Cl-Ado Has No Effect on the 1,25(OH)2D3-Induced Increase in Keratin 1 Protein Levels Figure 4
8-Cl-Ado Has No Effect on the 1,25(OH)2D3-Induced Increase in Keratin 1 Protein Levels. Near-confluent kerati-
nocytes were incubated for 24 hours with and without 25 µM 8-Cl-Ado in the presence and absence of 20 nM 1,25(OH)2D3 
and were then processed for western analysis. (A) A representative immunoblot is shown. (B) Keratin 1 levels were quantified, 
corrected for background and normalized for loading, as described in Materials and Methods. Data represent the mean ± SEM 
of four experiments performed in duplicate; *p < 0.05 versus the control value.BMC Pharmacology 2004, 4:13 http://www.biomedcentral.com/1471-2210/4/13
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or without different concentrations of 1,25(OH)2D3. After
24 hours, cells were labeled with 1 µCi/ml [3H]thymidine
for an additional hour in the continued presence of 8-Cl-
Ado and/or 1,25(OH)2D3. Cultures were washed twice
with phosphate-buffered saline without calcium or mag-
nesium (PBS-) and macromolecules were precipitated
using ice-cold 5% trichloroacetic acid (TCA). After addi-
tional washing with 5% TCA and distilled water, cells
were solubilized in 0.3 M NaOH, and the amount of
[3H]thymidine incorporated into DNA was determined by
liquid scintillation counting.
Measurement of transglutaminase activity
Transglutaminase activity was assessed essentially as
described in [33]. Briefly, near-confluent keratinocytes
were incubated for 24 hours with the indicated agents in
SFKM. The cells were scraped into homogenization buffer
(0.1 M Tris-acetate, pH 7.8, 2 µg/ml aprotinin, 2 µM leu-
peptin, 1 µM pepstatin A, 0.2 mM EDTA and 0.2 mM
PMSF), collected by centrifugation and subjected to one
freeze-thaw cycle prior to disruption by sonication. Aliq-
uots of the homogenate were removed for determination
of protein content and transglutaminase activity. Trans-
glutaminase activity was measured as the [3H]putrescine
radioactivity incorporated into casein after an overnight
incubation at 37°C. Casein was precipitated with TCA,
collected onto glass fiber filters and counted by liquid
scintillation spectrometry. The cellular protein content of
the samples was determined using the Bio-Rad DC pro-
tein assay system (Bio-Rad, Hercules, CA), with BSA as
standard, and transglutaminase activity was expressed as
cpm/µg protein.
Western analysis of keratin 1 protein levels
Keratinocytes were treated and solubilized in sample
buffer (31.2 mM Tris, pH 6.8, 1% SDS, 12.5% glycerol).
Equal sample volumes were separated by SDS polyacryla-
mide gel electrophoresis on an 8% gel and transferred to
Immobilon PVDF membrane (Millipore, Billerica, MA).
Membranes were blocked with Odyssey blocking buffer
(Licor Biosciences, Lincoln, NE), probed with a rabbit pol-
yclonal anti-keratin 1 antibody (Covance, Princeton, NJ)
and a mouse monoclonal anti-actin antibody (Sigma, St.
Loius, MO). Immunoreactive proteins were visualized
with IRDye800-coupled donkey anti-rabbit IgG (Rock-
land Immunochemicals, Gilbertsville, PA) or IR Alexa
Fluor 680-coupled goat anti-mouse IgG (Molecular
Probes, Eugene, OR) on a Licor Odyssey Infrared Imaging
System. Keratin-1 protein levels were corrected for back-
ground and normalized using background-corrected actin
levels.
Statistical analysis
Significance of differences was determined with the com-
puter program InStat (Graphpad Software, San Diego,
CA) using ANOVA with a Student-Newman-Keuls post-
hoc test.
Abbreviations
1,25(OH)2D3, 1,25-dihydroxyvitamin D3; 8-Cl-Ado, 8-
chloro-adenosine; 8-Cl-cAMP, 8-chloro-cyclic-adenosine
monophosphate; IC50, half-maximal inhibitory concen-
tration; TGFβ, transforming growth factor-beta
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